Physician profile

Smita Agarwal

Dermatology · Bridgewater, NJ

NPI 1982675633

$15,143.27

in general payments reported to CMS, 2019-2025

44 companies · $4,693 in 2025

The $4,693 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,005.42
Consulting Fee$2,602.66
Education$273.85

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Incyte Corporation $3,202.00 2021-2025 Opzelura
Abbvie INC. $1,186.01 2019-2025 Rinvoq, Skyrizi
Leo Pharma INC. $1,096.46 2019-2025 Adbry, Anzupgo
Genzyme Corporation $1,094.61 2020-2025
Sun Pharmaceutical Industries INC. $1,093.40 2019-2025 Winlevi, Ilumya, Blu-U
Janssen Biotech, INC. $1,026.17 2019-2025 Tremfya
Ucb, INC. $728.17 2019-2025 Bimzelx, Cimzia
Galderma Laboratories, L.P. $676.80 2019-2025 Nemluvio, Aklief, Oracea
Mayne Pharma Commercial LLC $669.04 2019-2025
Ortho Dermatologics, A Division of Bausch Health US, LLC $569.71 2019-2025 Siliq, Cabtreo
Regeneron Healthcare Solutions, INC. $445.00 2020-2025 Dupixent
Biofrontera INC. $414.57 2019-2021
Pfizer INC. $331.72 2019-2025
Sanofi-Aventis U.S. LLC $273.29 2020-2024
Lilly USA, LLC $266.37 2019-2025 Ebglyss, Taltz
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Amgen INC. $236.81 2019-2025 Otezla, Otezla
Vyne Pharmaceuticals INC. $221.67 2020-2021
Novartis Pharmaceuticals Corporation $219.73 2019-2025
Almirall LLC $206.03 2019-2025 Klisyri
E.R. Squibb & Sons, L.L.C. $164.11 2022-2025 Sotyktu
Epi Health, LLC $109.08 2019-2022
Arcutis Biotherapeutics, INC. $96.59 2023-2025 Zoryve
Helsinn Therapeutics (U.S.), INC. $85.49 2024-2025 Valchlor
Journey Medical Corporation $81.95 2020-2025
Dermavant Sciences, INC. $79.01 2023 Vtama
Dermira, INC. $68.00 2019-2020
Sebela Pharmaceuticals INC. $66.77 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $63.32 2022-2025 Spevigo
Genentech USA, INC. $54.19 2020-2022
Sensus Healthcare, INC. $39.52 2024
Merck Sharp & Dohme LLC $39.46 2019
Mallinckrodt Hospital Products INC. $39.45 2024 Acthar
Celgene Corporation $31.23 2019-2024 Sotyktu
Encore Dermatology INC. $28.87 2019
Fidia Pharma USA INC. $18.41 2025
Revance Therapeutics, INC. $17.67 2024 Daxxify
Mallinckrodt Enterprises LLC $14.35 2019
Aclaris Therapeutics, INC. $13.88 2019
Organogenesis INC. $13.25 2020
Janssen Pharmaceuticals, INC $13.17 2025 Tremfya
Sandoz INC. $12.76 2020
Promius Pharma LLC $12.21 2019
Paratek Pharmaceuticals, INC. $11.92 2021
Mission Pharmacal Company $11.05 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Smita Agarwal

$15,143.27

in general payments reported 2019-2025

Years
2019-2025
Top company
Incyte Corporation
Context
The $4,693 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).

https://glasscript.com/doctor/89978/smita-agarwal

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.